News | August 28, 2013

American Brachytherapy Society Receives $160,000 Grant from Nucletron

Grant is to support its residency training program

August 28, 2013 — Nucletron, an Elekta company, has signed an agreement with the American Brachytherapy Society (ABS) to continue to support the implementation of a residency-level training program in brachytherapy for radiation oncologists and physicists from the United States and other countries.

Brachytherapy is a form of radiation therapy in which a radiation source is placed inside or next to a tumor requiring treatment. It is commonly used as an effective treatment for gynecological cancers, as well as for cancers of the prostate, breast, skin, head and neck, and in other clinical situations in which soft tissue is involved.

"Because Elekta is dedicated to making cancer care technology as therapeutic and efficient as possible, we are committed to ensuring that users of our technology have access to high-quality, educational programs," says Jay Hoey, executive vice president, Elekta North America. "This is the reason why our partnership with ABS is so critical. It provides a key opportunity for young radiation oncologists and physicists to develop experience in brachytherapy."

ABS and Nucletron have had a long-standing partnership to promote the value of brachytherapy as a critically important modality in cancer management. As part of that relationship, one common goal is the need to provide educational opportunities to the worldwide brachytherapy community.

For the past six years, Nucletron has supported the ABS brachytherapy physician residency program, and has recently begun to establish a dedicated program for physicists as well.

For more information: www.americanbrachytherapy.org

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at